METHODS: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients.
RESULTS: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %-88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175).
CONCLUSIONS: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
方法:我们回顾性收集了来自中国36个中心的MBC患者的数据。通过Kaplan-Meier方法评估总生存期(OS),对数秩检验,和Cox回归分析。多因素Cox分析用于确定患者的独立预后因素。
结果:总计,纳入1119例患者。诊断时的平均年龄为60.9岁,并且随着时间的推移观察到显著的延长(P<0.001)。大多数患者(89.1%)接受了乳房切除术。在2009年或更早诊断的患者中,有7.8%进行了前哨淋巴结活检,这一比例在2020年及以后大幅上升至38.8%(P<0.001)。人口的五年OS率为85.5%[95%置信区间(CI),82.8%-88.4%]。多变量Cox分析确定了基于紫杉烷的[基于T,危险比(HR)=0.32,95%CI,0.13至0.78,P=0.012]和蒽环类抗生素加紫杉烷(基于A+T,HR=0.47,95%CI,0.23~0.96,P=0.037)方案作为OS的独立保护因素。然而,以蒽环类抗生素为基础的治疗方案在结局方面无显著性意义(P=0.175).
结论:作为中国最广泛的MBC研究,我们描述了特点,中国MBC人群的综合治疗和预后。在这些患者中,基于T和基于A+T的方案是OS的保护因素。对这个群体需要更多的研究。